The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
A Novel Protease And Growth Factor Regulated Signalling System In Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$856,743.00
Summary
Ovarian cancer is the leading cause of gynaecologic cancer death. Our project focuses on the role in ovarian cancer of a cellular receptor called CDCP1. We have previously shown that CDCP1 promotes growth and spread of ovarian tumours. Recently we have generated new data indicating that CDCP1’s activity is markedly increased by other proteins called proteases and growth factors. In this project we will define how these new pathways function, and if their blockade impedes ovarian cancer.
In melanoma we hypothesise there is a series of as yet unidentified gene fusions which provide oncogenic stimulatory signals that promote tumour growth and that these novel fusion products are excellent targets for the design of new therapies to treat melanoma. The aims of this study are to identify oncogenic fusions in melanoma, to assess which of these are recurrent, and to demonstrate that the resulting fusion proteins provide a selective growth and-or survival advantage to the tumour cell.
Wnt-5a Signalling - A Novel Therapy For Triple Negative And Tamoxifen Resistant Breast Cancer Patients
Funder
National Health and Medical Research Council
Funding Amount
$330,534.00
Summary
Breast cancer is the most common cancer in women. Commonly used drugs target the estrogen receptor (ER). However, one third of breast cancer patients lack ER, and do not respond to treatment. Cancers that lack ER also lack a gene called Wnt5a, which is linked to better prognosis. We have shown that fixing Wnt5a can restore ER allowing cells to respond to Tamoxifen. We would now test this in animals, in the hope of developing a new drug for breast cancer patients currently with limited options.